HEMCHAND KOLLI: Open Payments
NPI 1669552485 · HEMET, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,549 in 133 payments from 32 companies in 2025. Trend: 2023 $2,534 · 2024 $2,309 · 2025 $2,549
Food & beverage: $2,549
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $311 |
| Otsuka America Pharmaceutical, Inc. | 11 | $284 |
| Novo Nordisk Inc | 16 | $230 |
| GlaxoSmithKline, LLC. | 10 | $200 |
| Amgen Inc. | 23 | $158 |
| Janssen Biotech, Inc. | 1 | $150 |
| Lilly USA, LLC | 11 | $146 |
| Merck Sharp & Dohme LLC | 5 | $119 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $79 |
| Neurocrine BioSciences, Inc. | 4 | $79 |
Products named: REXULTI, TRELEGY ELLIPTA, TREMFYA, FARXIGA, AIRSUPRA, VERQUVO, OTEZLA, Wegovy.
Industry payments across CA — which companies pay providers there.
